Armistice Capital LLC purchased a new stake in shares of NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report) in the second quarter, Holdings Channel.com reports. The fund purchased 696,829 shares of the company’s stock, valued at approximately $3,373,000. Armistice Capital LLC owned 0.14% of NeuroBo Pharmaceuticals at the end of the most recent quarter.
Separately, Affinity Asset Advisors LLC bought a new stake in shares of NeuroBo Pharmaceuticals during the second quarter worth $432,000. Hedge funds and other institutional investors own 1.37% of the company’s stock.
NeuroBo Pharmaceuticals Stock Performance
Shares of NASDAQ:NRBO opened at $3.29 on Friday. The business has a fifty day moving average of $3.74 and a 200-day moving average of $3.97. NeuroBo Pharmaceuticals, Inc. has a twelve month low of $2.90 and a twelve month high of $6.75.
NeuroBo Pharmaceuticals Profile
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
Further Reading
- Five stocks we like better than NeuroBo Pharmaceuticals
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Rocket Lab Stock Soars: Should Investors Chase the Rally?
- What is the Australian Securities Exchange (ASX)
- KB Home Slips After Earnings: What’s Next for Homebuilders?
- Find and Profitably Trade Stocks at 52-Week Lows
- Micron Stock Soars as AI Demand Fuels Big Q4 Earnings Beat
Want to see what other hedge funds are holding NRBO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Free Report).
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.